Genetic Architecture of Familial Hypercholesterolaemia
- PMID: 28405938
- PMCID: PMC5389990
- DOI: 10.1007/s11886-017-0848-8
Genetic Architecture of Familial Hypercholesterolaemia
Abstract
Purpose of review: Familial hypercholesterolaemia (FH) is an inherited disorder of low-density lipoprotein cholesterol (LDL-C) which is characterised by a raised cholesterol level from birth and a high risk of premature coronary heart disease. In this paper, we review the genetic basis of FH and its impact on the clinical presentation.
Recent findings: Mutations in any of three genes (LDLR, APOB and PCSK9) are known to cause autosomal dominant FH, but a mutation can be found in only ∼40% of patients with a clinical diagnosis of FH. In the remainder, a polygenic aetiology is most likely, due to the co-inheritance of common LDL-C-raising variants. The cardiovascular presentation and management of FH will differ between patients based on their underlying genetic factors. New genotyping methods such as next-generation sequencing will provide us with better understanding of the genetic architecture of FH.
Keywords: APOB gene; Familial hypercholesterolaemia; LDLR gene; PCSK9 gene; Polygenic hypercholesterolaemia.
Conflict of interest statement
Conflict of Interest
Mahtab Sharifi declares that she has no conflict of interest.
Marta Futema reports speakers’ fees from Sanofi.
Devaki Nair has received grants from Pfizer (Pfizer Foundation award 2008), Solvay, Merck Sharp & Dohme, and Astra Zeneca. DN has advisory board membership with Merck Sharp & Dohme, Sanofi, Amgen and Astra Zeneca.
Steve E. Humphries is the Medical director of a UCL spin-out company StoreGene that offers to clinicians genetic testing for patients with familial hypercholesterolaemia.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Figures

Similar articles
-
The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes.Clin Genet. 2020 Mar;97(3):457-466. doi: 10.1111/cge.13697. Clin Genet. 2020. PMID: 31893465
-
Molecular genetics of familial hypercholesterolemia in Israel-revisited.Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18. Atherosclerosis. 2017. PMID: 28104544
-
Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia.Clin Genet. 2020 Nov;98(5):457-467. doi: 10.1111/cge.13826. Epub 2020 Sep 2. Clin Genet. 2020. PMID: 32770674
-
Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?Clin Genet. 2020 Apr;97(4):543-555. doi: 10.1111/cge.13685. Epub 2019 Dec 27. Clin Genet. 2020. PMID: 31833051 Review.
-
Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.Atherosclerosis. 2018 Oct;277:457-463. doi: 10.1016/j.atherosclerosis.2018.06.006. Atherosclerosis. 2018. PMID: 30270085 Review.
Cited by
-
Correlation Between the APOB rs1042034 SNP and Blood Lipid Characteristics of 2 Ethnic Groups in China.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619892088. doi: 10.1177/1076029619892088. Clin Appl Thromb Hemost. 2019. PMID: 31833377 Free PMC article.
-
Screening of common genetic variants in the APOB gene related to familial hypercholesterolemia in a Saudi population: A case-control study.Medicine (Baltimore). 2019 Jan;98(4):e14247. doi: 10.1097/MD.0000000000014247. Medicine (Baltimore). 2019. PMID: 30681615 Free PMC article.
-
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?Curr Atheroscler Rep. 2021 Apr 1;23(6):28. doi: 10.1007/s11883-021-00915-6. Curr Atheroscler Rep. 2021. PMID: 33791884 Free PMC article. Review.
-
Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.Genes (Basel). 2022 Jun 1;13(6):999. doi: 10.3390/genes13060999. Genes (Basel). 2022. PMID: 35741760 Free PMC article.
-
The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia.Int J Cardiol Heart Vasc. 2019 May 3;23:100354. doi: 10.1016/j.ijcha.2019.100354. eCollection 2019 Jun. Int J Cardiol Heart Vasc. 2019. PMID: 31080874 Free PMC article.
References
-
- DeMott KNL, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous